needlefre
vaccin
via
mucos
rout
drawn
increas
recent
attent
vaccin
deliveri
strategi
ideal
vaccin
infecti
pathogen
prime
host
induct
pathogenspecif
memori
immun
respons
appropri
mucos
compart
therebi
prevent
entri
andor
replic
invad
pathogen
site
infect
mucos
immun
via
nasal
buccal
sublingu
rout
recent
emerg
altern
intramuscular
im
vaccin
administr
nonparenter
needlefre
mucos
vaccin
sever
advantag
includ
reduc
pain
stress
cost
viral
transmiss
associ
inject
current
studi
establish
sublingu
sl
immun
effici
stimul
mucos
immun
induc
system
humor
immun
cytotox
lymphocyt
ctl
respons
recent
year
number
studi
explor
potenti
sl
immun
elicit
desir
immun
respons
variou
potenti
vaccin
compon
includ
protein
antigen
liveattenu
virus
howev
studi
investig
sl
deliveri
dna
vaccin
use
viral
vector
previou
studi
construct
human
endogen
retroviru
herv
envelopeco
nonreplic
baculovirusbas
dna
vaccin
human
papillomaviru
achervhpv
im
administr
achervbas
monoval
bival
trival
achervtrihpv
gene
construct
induc
high
level
humor
cellular
immunogen
provid
complet
protect
hpv
typespecif
pseudovirus
pv
test
whether
dna
vaccin
encapsid
acherv
system
could
deliv
via
sl
rout
administ
achervtrihpv
mice
sublingu
without
adjuv
report
immunogen
achervtrihpv
follow
sl
immun
achervtrihpv
produc
use
bactobac
baculoviru
express
system
invitrogen
ca
usa
accord
manufactur
instruct
briefli
recombin
baculoviru
construct
encod
codonoptim
envelop
gene
human
endogen
retroviru
herv
genbank
access
number
genscript
corp
piscataway
nj
usa
sequenc
three
hpv
gene
kindli
suppli
dr
schiller
nation
cancer
institut
nation
institut
health
usa
control
human
elong
promot
spodoptera
frugiperda
cell
invitrogen
catalog
cultur
ii
medium
invitrogen
supplement
unitsml
gibco
antibioticantimycot
invitrogen
achervtrihpv
amplifi
propag
cell
purifi
first
centrifug
minut
remov
virusinfect
cell
debri
thereaft
supernat
overlaid
sucros
cushion
centrifug
rpm
hour
rotor
beckman
coulter
inc
ca
usa
pellet
resuspend
phosphatebuff
salin
pb
invitrogen
use
immun
sixweekold
femal
balbc
mice
purchas
orientbio
seungnam
kyonggido
republ
korea
hous
filtertop
cage
water
food
provid
ad
libitum
mice
maintain
accord
guid
care
use
laboratori
anim
konkuk
univers
seoul
republ
korea
hous
biosafeti
level
facil
use
anim
experi
approv
institut
anim
care
use
committe
konkuk
univers
approv
throughout
studi
condit
anim
monitor
twice
day
studi
mice
exhibit
symptom
ill
appear
close
death
moreov
mice
die
monitor
phase
final
monitor
mice
human
euthan
use
cervic
disloc
accord
avma
guidelin
euthanasia
anim
biodistribut
studi
achervtrihpv
sublingu
administ
level
achervtrihpv
variou
tissu
measur
use
quantit
realtim
polymeras
chain
reaction
qrtpcr
mice
anesthet
mgkg
zoletil
virbac
laboratori
carro
franc
mgkg
rompun
bayer
korea
seoul
republ
korea
mice
sublingu
administ
copi
achervtrihpv
use
previous
report
procedur
mice
sacrif
inhal
variou
time
point
tissu
collect
total
blood
tissu
dna
extract
use
dneasi
tissu
kit
qiagen
valencia
ca
usa
describ
manufactur
qrtpcr
serial
dilut
plasmid
encod
encompass
concentr
rang
use
construct
standard
curv
level
gene
mous
sampl
determin
qpcr
amplif
genom
dna
gdna
templat
ng
use
lightcycl
faststart
dna
master
sybr
green
roch
diagnost
gmbh
mannheim
germani
amplif
condit
consist
initi
denatur
step
minut
follow
cycl
second
second
second
primer
detect
cga
gac
cac
cta
caa
forward
primer
gtt
cat
gct
gtg
gat
revers
primer
gener
product
amplif
glyceraldehyd
phosphat
dehydrogenas
gapdh
mrna
use
control
effici
qrtpcr
among
sampl
mice
immun
achervtrihpv
vaccin
via
sl
im
rout
depict
fig
mice
receiv
three
immun
dose
interv
rout
sl
immun
mice
anesthet
mgkg
zoletil
virbac
laboratori
mgkg
rompun
bayer
korea
mice
receiv
differ
dose
sublingu
deliv
achervtrihpv
use
previous
describ
procedur
prevent
swallow
sl
immun
total
volum
inoculum
limit
im
immun
mice
intramuscularli
inject
hind
leg
copi
achervtrihpv
comparison
mice
immun
three
time
cervarix
glaxosmithklin
middlesex
uk
human
dose
serum
vagin
sampl
collect
week
first
immun
day
via
sl
im
rout
fig
serum
sampl
obtain
centrifug
whole
blood
collect
right
extern
jugular
vein
vagin
secret
sampl
collect
rins
vagin
caviti
five
time
pb
vagin
secret
sampl
microcentrifug
rpm
minut
supernat
collect
store
analyz
hpv
typespecif
pv
produc
previous
describ
capsidencod
plasmid
use
produc
pv
pv
pv
respect
neutral
assay
pyseap
secret
alkalin
phosphatas
seap
express
plasmid
encapsid
vivo
imag
plasmid
pclucf
firefli
luciferas
express
plasmid
encapsid
plasmid
use
vitro
vivo
assay
prepar
describ
nation
cancer
institut
websit
http
homeccrcancergovlcodefaultasp
level
antibodi
specif
measur
enzymelink
immunosorb
assay
elisa
precious
describ
briefli
elisa
plate
coat
pv
incub
hour
plate
wash
block
wv
bovin
serum
albumin
serial
dilut
mous
sera
vagin
secret
sampl
ad
incub
hour
room
temperatur
wash
plate
incub
peroxidaseconjug
goat
antimous
igg
antibodi
santa
cruz
biotechnolog
santa
cruz
ca
usa
goat
antimous
iga
antibodi
santa
cruz
biotechnolog
hour
color
develop
turbo
tmb
benzidin
substrat
solut
pierc
usa
ad
reaction
stop
ad
absorb
measur
nm
endpoint
titer
defin
highest
serum
dilut
result
absorb
nonimmun
serum
reach
cutoff
valu
express
group
geometr
mean
sd
neutral
assay
perform
use
seapexpress
pv
accord
previous
describ
method
briefli
optipreppurifi
seap
pv
dilut
incub
ice
hour
serial
dilut
serum
cell
infect
incub
mixtur
hour
seap
content
clarifi
cell
supernat
determin
use
great
escap
seap
chemiluminesc
kit
clontech
mountain
view
ca
usa
neutral
titer
defin
reciproc
highest
serum
dilut
caus
least
reduct
seap
activ
induct
cell
determin
measur
product
use
enzymelink
immunospot
elispot
assay
two
week
final
immun
achervtrihpv
splenocyt
isol
immun
mice
elispot
plate
elispot
kit
bd
bioscienc
san
jose
ca
usa
coat
antimous
captur
antibodi
plate
block
incub
fetal
bovin
serum
seed
splenocyt
cell
per
well
medium
stimul
copi
pv
ad
plate
incub
hour
plate
wash
pb
contain
treat
ng
biotinyl
antimous
detect
antibodi
hour
streptavidinalkalin
phosphatas
ad
color
develop
use
aminoethylcarbazol
aec
substrat
reagent
bd
bioscienc
number
spot
count
use
elispot
reader
aid
elispot
reader
ver
aid
gmbh
germani
three
week
final
immun
achervtrihpv
mice
challeng
hpv
pv
describ
previous
seven
day
vivo
genit
challeng
pv
mice
synchron
diestruslik
statu
subcutan
inject
mg
depoprovera
pfizer
ag
zurich
switzerland
six
hour
prior
pv
challeng
deepli
anesthet
mice
intravagin
pretreat
sigma
st
loui
mo
usa
mice
genit
challeng
copi
pv
pv
pv
solut
contain
carboxymethylcellulos
sigma
hpv
infect
monitor
measur
luciferas
express
genit
tract
day
postchalleng
final
day
anesthet
mice
instil
intraperiton
mg
pb
luciferin
calip
life
scienc
hopkinton
usa
luciferas
express
visual
light
emiss
measur
molecular
imag
acquir
minut
use
ivi
bioluminesc
imag
system
xenogen
cranburi
nj
usa
equal
area
encompass
site
viru
inocul
analyz
use
live
imag
softwar
xenogen
data
analyz
analysi
varianc
anova
post
hoc
studentnewmankeul
test
use
sigmastat
softwar
systat
softwar
san
jose
ca
usa
pvalu
less
consid
signific
sublingu
administ
achervtrihpv
absorb
distribut
throughout
bodi
fig
achervtrihpv
detect
blood
thymu
cervic
lymph
node
spleen
liver
lung
kidney
brain
heart
minut
postdos
thymu
spleen
lung
brain
heart
show
level
greater
copi
per
ng
gdna
minut
postdos
one
day
sl
immun
distribut
spleen
decreas
less
copi
per
ng
gdna
distribut
kidney
increas
greater
copi
per
ng
gdna
minut
day
sl
administr
highest
distribut
achervtrihpv
observ
lung
fig
level
achervtrihpv
decreas
throughout
bodi
time
thirti
day
sl
administr
tissu
show
level
achervtrihpv
greater
copi
per
ng
gdna
achervtrihpv
administ
three
time
sl
im
rout
inject
sampl
scheme
shown
fig
sl
immun
achervtrihpv
induc
typespecif
humor
immun
respons
compar
observ
follow
im
immun
induc
serum
igg
antibodi
fig
fig
fig
sl
administr
achervtrihpv
induc
dosedepend
increas
serum
igg
antibodi
rang
copi
clearli
observ
week
first
immun
howev
dosedepend
serum
igg
antibodi
product
disappear
week
first
sl
immun
moreov
week
first
immun
level
serum
igg
significantli
differ
sl
im
immun
notabl
induct
serum
igg
sl
immun
copi
achervtrihpv
compar
induc
im
immun
copi
week
first
immun
although
serum
igg
induct
sl
immun
show
littl
sustain
dose
depend
vagin
iga
level
increas
dosedepend
manner
sl
immun
achervtrihpv
induc
vagin
iga
fig
fig
fig
three
type
iga
highest
iga
antibodi
titer
observ
sl
immun
highest
dose
copi
six
week
first
immun
level
vagin
iga
follow
sl
immun
copi
compar
follow
im
immun
dose
sl
administr
achervtrihpv
induc
typespecif
neutral
antibodi
pv
fig
pv
fig
pv
fig
similar
serum
igg
antibodi
fig
serumneutr
antibodi
induc
dosedepend
manner
sublingu
administ
achervtrihpv
week
first
administr
neutral
antibodi
titer
significantli
differ
among
three
dose
week
first
immun
consist
abil
induc
serum
igg
fig
sl
immun
copi
achervtrihpv
induc
neutral
antibodi
week
first
immun
degre
compar
im
immun
copi
sl
immun
three
dose
achervtrihpv
induc
cell
respons
hpv
typespecif
dosedepend
manner
splenic
cell
respons
detect
use
elispot
assay
sl
immun
achervtrihpv
increas
product
fig
fig
splenic
cell
stimul
pv
although
serum
igg
product
fig
neutral
antibodi
induct
fig
show
littl
depend
dose
sublingu
administ
achervtrihpv
cellular
immun
respons
dose
depend
follow
sl
immun
copi
achervtrihpv
produc
least
higher
product
regardless
stimul
hpv
type
compar
copi
fig
term
cell
respons
copi
sublingu
administ
achervtrihpv
induc
least
higher
product
copi
except
case
stimul
pv
fig
sl
immun
copi
achervtrihpv
induc
cellular
respons
compar
induc
im
immun
copi
test
whether
neutral
antibodi
titer
gener
sl
administr
achervtrihpv
could
protect
mice
hpv
infect
challeng
immun
mice
pv
via
vagin
rout
genit
pseudoinfect
pv
detect
monitor
express
luciferas
report
gene
use
wholeorgan
multispectr
molecular
imag
fig
nonimmun
mice
challeng
luciferaseencod
pv
fig
pv
fig
pv
fig
exhibit
strong
luminesc
intens
reflect
effect
vagin
pseudoinfect
pv
mice
immun
sl
administr
copi
achervtrihpv
show
dim
luminesc
smaller
spot
area
challeng
pv
fig
pv
fig
pv
fig
howev
mice
immun
sl
administr
fig
fig
copi
achervtrihpv
show
luminesc
challeng
pv
fig
pv
fig
pv
fig
mice
immun
im
administr
copi
achervtrihpv
show
luminesc
challeng
pv
fig
pv
fig
pv
fig
demonstr
humor
cellular
immunogen
sublingu
administ
achervtrihpv
hpv
type
sl
immun
achervtrihpv
protect
mice
challeng
hpv
typespecif
pv
moreov
sublingu
administ
achervtrihpv
show
higher
distribut
lung
compar
tissu
minut
hour
administr
persist
lung
hour
higher
level
achervtrihpv
lung
earli
time
point
support
interpret
sublingu
administ
achervtrihpv
directli
absorb
lung
rather
system
absorb
blood
subsequ
distribut
lung
like
system
absorpt
achervtrihpv
involv
paracellular
transcellular
pathway
across
sublingu
epitheli
cell
report
sublingu
administ
antigen
transport
across
ductal
sl
epitheli
cell
reach
ductal
antigenpres
cell
mice
addit
possibl
sublingu
administ
achervtrihpv
reach
lung
part
migrat
sl
dendrit
cell
captur
antigen
consist
possibl
recent
studi
report
antigendisplay
dendrit
cell
sl
mucosa
detect
distant
lymph
node
spleen
observ
distribut
achervtrihpv
brain
follow
sl
administr
previou
studi
report
sublingu
administ
viral
vaccin
migrat
brain
song
et
al
report
live
influenza
viru
detect
olfactori
bulb
brain
tissu
one
day
sl
administr
shim
et
al
observ
sublingu
administ
recombin
adenoviru
encod
acut
respiratori
syndromeassoci
coronaviru
sarscov
detect
olfactori
bulb
conclud
redirect
viru
brain
given
previou
report
unlik
achervtrihpv
directli
migrat
brain
via
olfactori
bulb
rather
exist
possibl
system
absorb
achervtrihpv
might
distribut
brain
pass
bloodbrain
barrier
inde
previous
observ
brain
distribut
acherv
encod
follow
intramuscular
administr
studi
distribut
level
intramuscularli
administ
acherv
encod
similar
among
brain
heart
lung
tissu
similar
previou
report
brain
distribut
porcinederiv
adenoassoci
viru
observ
follow
intraven
inject
mice
sl
administr
achervtrihpv
induc
serum
igg
vagin
iga
extent
compar
intramuscularli
administ
achervtrihpv
previous
show
sl
administr
protein
induc
humor
cellular
immun
respons
howev
latter
studi
alon
effect
induc
immunogen
requir
coadministr
adjuv
cholera
toxin
b
induc
prolong
cellular
immunogen
although
interconnect
mucos
system
immun
system
remain
studi
exclud
possibl
type
antigen
vaccin
deliveri
system
may
affect
effici
mucos
immunogen
follow
system
mucos
administr
previou
studi
report
vagin
iga
immun
respons
bovin
papillomaviru
type
viruslik
particl
compar
follow
intranas
intramuscular
administr
case
chimer
bovin
papillomaviru
viruslik
particl
incorpor
sequenc
human
immunodefici
vagin
iga
induct
higher
follow
im
administr
compar
intravagin
administr
intramuscular
administr
integrasedefect
lentivir
vector
carri
ovalbumin
gene
follow
sublingu
ovalbumin
administr
report
induc
persist
vagin
iga
immun
respons
recent
studi
report
sl
immun
femal
human
volunt
gardasil
induc
lower
serum
igg
level
lower
cervicalvagin
igg
level
im
immun
highlight
import
deliveri
system
sl
immun
observ
sl
im
immun
mice
achervtrihpv
induc
immun
respons
fig
plasmid
dna
vaccin
known
induc
typespecif
immun
respons
observ
immun
respons
might
explain
adjuv
activ
acherv
baculovir
vector
previou
studi
report
role
viral
vector
activ
cell
subset
immun
respons
observ
adenoassoci
viral
aav
vector
express
coagul
factor
ix
could
activ
helper
cell
primarili
subset
wherea
adenovir
vector
effici
activ
coagul
factor
ixspecif
ctl
helper
cell
subset
baculoviru
report
induc
immun
respons
mice
follow
intramuscular
inject
induc
baculovirusspecif
splenocyt
intranas
immun
recombin
baculovirusbas
vaccin
express
shown
induc
respons
splenocyt
mice
thu
specul
acherv
baculovir
vector
could
stimul
activ
cell
subset
express
hpv
antigen
sl
immun
mice
achervtrihpv
complet
protect
vagin
challeng
hpv
typespecif
pv
notabl
sl
immun
achervtrihpv
protect
mice
challeng
via
vagin
rout
protect
pv
indic
sl
immun
capabl
induc
level
hpv
typespecif
vagin
iga
suffici
neutral
mucosainfect
hpv
sl
administr
hpv
viruslik
particl
shown
induc
serumneutr
antibodi
vagin
iga
studi
sl
administr
hpv
viruslik
particl
provid
protect
genit
challeng
hpv
pv
previou
studi
report
sl
immun
ovalbumin
plu
alphagalactosylceramid
protect
mice
intraven
lung
tumor
challeng
anoth
studi
show
sl
immun
domain
botulinum
neurotoxin
heavi
chain
fuse
adenoviru
fiber
protein
protect
mice
intraperiton
challeng
botulinum
neurotoxin
deliveri
trival
hpv
via
acherv
system
induc
humor
cellular
immunogen
absenc
adjuv
sever
studi
sought
develop
antigen
deliveri
system
suitabl
sl
rout
includ
multilay
film
tablet
adjuvantfre
sl
vaccin
may
benefici
reduc
cost
vaccin
prepar
elimin
concern
safeti
adjuv
conclus
sl
administr
achervtrihpv
induc
humor
cellular
immun
respons
extent
compar
im
administr
induct
immunogen
use
sublingu
administ
achervtrihpv
achiev
without
coadministr
adjuv
extent
mucos
immunogen
suffici
provid
complet
protect
vagin
challeng
pv
although
studi
specif
demonstr
feasibl
use
acherv
system
sl
deliveri
multival
hpv
acherv
system
could
use
futur
induc
immunogen
mucosainfect
virus
influenza
human
immunodefici
virus
